Shares of Egalet Corp (NASDAQ: EGLT), engaged in developing and commercialising proprietary, abuse-deterrent oral products for the treatment of pain and in other indications, recorded over 23.0% gain during each of the past two consecutive trading sessions with significant number of shares exchanging hands. EGLT was among the top performers in the U.S. healthcare sector after gaining 39.7% and closed at $8.54 Friday, while recording significant trading volumes of 428,967 shares. EGLT’s stock has witnessed price rise due to the recent announcement made by EGLT about positive top-line results from oral human abuse liability study of abuse-deterrent morphine, egalet-001. During the past 5-trading sessions, EGLT gained 72.5% with daily average trading volumes of 132,549 shares, while the stock accumulated 40.5% gain during the past one month with daily average trading volumes of 32,028 shares. The stock is up 50.1% year-to-date.
Company Description:
Egalet Corporation (NASDAQ: EGLT) is a specialty pharmaceutical company. The company develops and markets oral products for the treatment of pain and in other indications.
1-Year Stock Chart:
Source: Bloomberg
